Company intelligence / Profile preview

Activeyes

Research Triangle Park, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

ActivEye was a clinical-stage biotechnology company focused on developing sustained-release drug delivery technologies for the treatment of retinal diseases. The company's primary asset was a bioerodible, injectable implant designed to deliver therapeutic agents, such as Rho kinase (ROCK) inhibitors, to the back of the eye over several months. This technology aimed to reduce the frequency of intravitreal injections for patients with conditions like wet age-related macular degeneration (AMD) and diabetic macular edema. ActivEye was acquired by Aerie Pharmaceuticals in 2017 to bolster Aerie's pipeline in retinal disease management.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeHydrogel-based drug delivery therapy
Industry: Biotech

Partnerships

Aerie Pharmaceuticals

Beyond the preview

Go deeper on Activeyes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Activeyes.

Explore the full profile